Global Anti-Neoplastic Agents Market Size To Reach USD 233 Billion By 2028

25-Mar-2022 | Facts and Factors

According to the Facts & Factors report, the global anti-neoplastic agents market was worth about 108 (USD Billion) in 2021 and is predicted to grow to around 233 (USD Billion) by 2028, with a compound annual growth rate (CAGR) of around 7.5%. The report explores various factors and their implications on the anti-neoplastic agents market’s growth.

Antineoplastic medicines are cancer-fighting treatments. Chemotherapy, anticancer, cytotoxic, and hazardous medications are all examples of antineoplastic drugs. These medications come in a variety of formats. Some are fluids that are administered to the patient, while others are pills that the patient swallows. Gleevec, Oncotrex, Leueran, Neosar, Cytarine, and other anti-neoplastic medicines are commercially marketed for the treatment of many forms of cancer. Several new anti-neoplastic drugs are currently in clinical trials, including Oncofetal Ag (phase 1), Volasertib (phase 2), Panobinostat (phase 2), Bortezomib (phase 4), and others, and are likely to be available in the next 5–10 years.

Browse the full “Anti-Neoplastic Agents Market By Type of Product (Biological Agents, Personalized Medicine, and Chemotherapeutic Agents), By End-User (Cancer Rehabilitation Centers, Clinics, Hospitals, and Ambulatory Surgical Centers), and By Region-Global and Regional Industry Overview, Market Insights, Holistic Investigation, Historical Information, and Forecast 2022–2028”  report at https://www.fnfresearch.com/toc/anti-neoplastic-agents-market

Cancer, as well as other diseases, is becoming more common, and people are becoming more aware of the numerous sorts of therapies available. The expansion of the healthcare system in emerging nations is expected to boost the growth of the global anti-neoplastic agents market throughout the forecast period. Furthermore, government measures to regulate safety standards, as well as severe medication manufacturing laws, are projected to contribute to favorable sales growth in this market over the next several years.

One of the primary factors impeding the development of anti-neoplastic therapy is the exorbitant cost of the medicines. Even in poor nations like India, where cancer treatments are relatively inexpensive, cancer therapy can range from USD 3000 to USD 12,000 depending on the stage and type of cancer. Needless to add, the same treatments in North America and Europe can cost an arm or a leg. Furthermore, a scarcity of experienced specialists with in-depth knowledge of the field may stymie the expansion of the anti-neoplastic agents market.

The global anti-neoplastic agents market is segregated on the basis of type of product, end-user, and region. By type of product, the market is divided into biological agents, personalized medicine, and chemotherapeutic agents. Chemotherapeutic agents account for a major portion of the market revenue. Because of the ease with which pharmaceuticals are available, the chemotherapeutic agent's category is expected to lead the market. The market for immunotherapeutic agents is predicted to expand as biological therapy acceptability grows due to fewer adverse effects. By end-user, the market is classified into cancer rehabilitation centers, clinics, hospitals, and ambulatory surgical centers. The hospital segment accounted for a sizable portion of market revenue. According to the Healthcare Cost and Utilization Project, there were 36.2 million hospital admissions connected to cancer in the United States in 2019. 

In 2021, North America owned the greatest share of the global anti-neoplastic agents market, accounting for 34% of the total. Obesity on a vast scale in the US is one of the major causes of this segment's rise, as does the continent's expanding older population, which plays a vital role as risks of cancer increase with age, and reduced immunity due to the high consumption of fast meals. For instance, the senior population currently accounts for 16 percent of the total population and is expected to increase to 22 percent by 2040, or over 85.5 million people. However, the Asia Pacific region is anticipated to witness the fastest-growing segment between 2022 and 2028. The expansion in this region is due to factors such as an increase in communicable and cancer cases with a growing population, developing-country GDPs such as China & India, resulting in further investment in state-of-the-art healthcare and research infrastructure. 

Report Scope

Some of the main competitors dominating the global anti-neoplastic agents market are Baxter Healthcare Corporation, Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Lundbeck LLC, Bristol-Myers Squibb Company, Johnson & Johnson Pvt. Ltd., Amgen Inc., Aspen Global Inc., Genentech Inc., AbbVie Inc., Accord Healthcare Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Bayer AG, and Pfizer Inc.

Recent Developments

• November 2021: The FDA has accepted the classification of "orphan drug" for CTC's wholly-owned therapeutically candidate, LYT-200, for treating pancreatic cancer, according to the US-based clinical-stage therapeutic firm, "PureTech." LYT-200 is a fully human IgG4 monoclonal antibody that targets galectin-9, a basic immunosuppressive protein, for the potential treatment of solid tumors such as colorectal cancer, pancreatic ductal adenocarcinoma, and cholangiocarcinoma, which are difficult to treat and have low survival rates.
• November 2021: Roswell Park Comprehensive, a cancer clinic in New York, did research and discovered that there is a strong relationship between cancer and stress. According to the study's findings, people who experience greater levels of stress are much more prone to developing cancer cells. It was also discovered that when tumors grow, they become even more susceptible to stress signals from the central nervous system. The researchers revealed that a subset of immune cells called myeloid-derived suppressor cells expresses more β-AR, a protein that regulates the function of important immune cells. 

The global anti-neoplastic agents market is segmented as follows:

By Type of Product

• Biological Agents
• Personalized Medicine
• Chemotherapeutic Agents

By End-User

• Cancer Rehabilitation Centers
• Clinics
• Hospitals
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Reunion
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Southeast Asia
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com